Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma

British Journal of Dermatology

Volumn 134, Issue 5, 1996, Pages 843-847

  Ihn, H ^a,b   Sato, S ^a   Fujimoto, M ^a   Kikuchi, K ^a   Takehara, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCLERODERMA; SYSTEMIC SCLEROSIS;

EID: 0029983817     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb06313.x     Document Type: Article

References (22)

1. Rodnan GP. When is scleroderma not scleroderma? Bull Rheum Dis 1981; 31: 7-10.
2. Christianson HB, Dorsey CS, O'Leary PA, Kierland RR. Localized scleroderma: a clinical study of 235 cases. Arch Dermatol 1956; 74: 629-39.
3. Scarola JA, Shulman LE. Serologic abnormalities and their significance in localized scleroderma. Arthritis Rheum 1975; 18: 526 (Abstract).
4. Rodnan GP, Rabin BS, Reichlin M. Eosinophilia and serological abnormalities in linear localized scleroderma. Arthritis Rheum 1977; 20: 133 (Abstract).
5. Takehara K, Moroi Y, Nakabayashi Y et al. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983; 26: 612-16.
6. Woo Ty, Rasmussen JE. Juvenile linear scleroderma associated with serological abnormalities. Arch Dermatol 1985; 121: 1403-5.
7. Falanga V, Medsger TA Jr, Reichlin M et al. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986; 104: 849-57.
8. Takehara K, Kikuchi K, Soma Y et al. Anti-single-strand DNA antibody and muscle involvement in localized scleroderma. Arch Dermatol 1990; 126: 1368-9.
9. Sato S, Ihn H, Soma Y et al. Antihistone antibodies in localized scleroderma. Arthritis Rheum 1993; 36: 1137-41.
10. Ihn H, Sato S, Fujimoto M et al. Demonstration of interleukin-2, interleukin-4, and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287; 193-7.
11. Leonard WJ, Depper JM, Robb RJ et al. Characterization of the human receptor for T cell growth factor. Proc Natl Acad Sci USA 1983; 80: 6957-61.
12. Rubin LA, Kurman CC, Fritz ME et al. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 1985; 135: 3172-7.
13. Rubin LA, Snow KM, Kurman CC et al. Serial levels of interleukin-2 receptor in the peripheral blood of patients with rheumatoid arthritis: correlation with disease activity. J Rheumatol 1990; 17: 597-602.
14. Wolfe RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988; 31: 729-35.
15. Ter Borg EJ, Horst G, Limburg PC et al. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990; 82: 21-6.
16. Wood NC, Symons JA, Duff GW. Serum interleukin-2 receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmunity 1988; 1: 353-61.
17. Degiannis D, Seibold JR, Czarnecki M et al. Soluble interleukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 1990; 33: 375-80.
18. Subcommittee for Scleroderma Criteria of the ARA Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-9.
19. Takehara K, Moroi Y, Ishibashi Y. Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol 1985; 112: 23-33.
20. Ihn H, Sato S, Tamaki T et al. Clinical evaluation of scleroderma spectrum disorders using a point system. Arch Dermatol Res 1992; 284: 391-5.
21. Smith KA. Interleukin 2. Annu Rev Immunol 1984; 2: 319-333.
22. Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993; 73: 5-8.